Company intelligence / Profile preview
Fractyl Health
Burlington, Massachusetts, United Statesfractyl.com ↗
- Ownership
- Public · GUTS
- Employees
- ~107
- Development stage
- Phase 1
01
Overview
Fractyl Health is entering pivotal studies for its Revita procedure, which aims to be an 'off ramp' to GLP-1 medications. The company has received FDA breakthrough designation for Revita for patients who have stopped taking GLP-1 drugs. They recently pivoted from Type 2 diabetes studies to focus on Revita for obesity management.
- Therapeutic areas
- Endocrinology
- Modalities
- Endoscopic procedureGene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Financials
- Market cap
- $11.9M
- Total revenue
- $0
- Enterprise value
- $25.5M
Beyond the preview
Go deeper on Fractyl Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fractyl Health.